Editas Medicine, Inc.
Ticker
EDIT
ISIN
US28106W103
Price
USD 5.51
Change Today
-0.01 / -0.181 %
Price 1 year ago
9.61 / -42.664 %
Market Capitalization
1,014,349,696.00
52 Week Low
5.03
52 Week High
11.47
200 Day Moving Average
8.04
50-day Moving Average
6.39
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NMS
Earnings Per Share
-1.979
P/E Ratio
-
Debt/Equity Ratio
4.517
Beta
1.93146
Ebitda
-181,564,992.00
-
Enterprise to Ebitda
-3.45
Enterprise Value
626,308,416.00
Target Price
32.23
Estimated Price
-
Book Value
6.29
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
Company | Name | Correlation |
---|---|---|
300181.SZ | ZHEJIANG JOLLY PHA | -0.67 |
600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | -0.55 |
600866.SS | STAR LAKE BIOSCIENCE CO INC Z | -0.43 |
IMU.AX | IMUGENE FPO | -0.42 |
300204.SZ | STAIDSON (BEIJING) | -0.32 |
300009.SZ | ANHUI ANKE BIOTECH | -0.19 |
002252.SZ | S/H RAAS BLOOD PRO | -0.03 |
2137.HK | BRII-B | 0.01 |
ALPHA.PA | PHARNEXT | 0.10 |
2370.T | MEDINET CO LTD | 0.14 |
TRX.L | TISSUE REGENIX GROUP PLC | 0.14 |
1530.HK | 3SBIO | 0.21 |
0775.HK | CKLIFE SCIENCES | 0.25 |
1873.HK | VIVA BIOTECH | 0.27 |
600201.SS | JINYU BIO-TECHNOLOGY CO LTD | 0.29 |
AKBA | Akebia Therapeutics, Inc. | 0.29 |
1177.HK | SINO BIOPHARM | 0.30 |
300147.SZ | XIANGXUE PHARMACEU | 0.30 |
300497.SZ | JIANGXI FUSHINE PH | 0.31 |
002007.SZ | HUALAN BIOLOGICAL | 0.36 |
300363.SZ | PORTON PHARMA SOLU | 0.43 |
TMBR | Timber Pharmaceuticals, Inc. | 0.44 |
2269.HK | WUXI BIO | 0.46 |
BLUE | bluebird bio, Inc. | 0.48 |
ATHX | Athersys, Inc. | 0.55 |
1801.HK | INNOVENT BIO | 0.56 |
DNA | Ginkgo Bioworks Holdings, Inc. | 0.61 |
300122.SZ | CHONGQING ZHIFEI B | 0.66 |
Similar companies
Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
---|---|---|---|---|---|---|---|---|---|
ALPHA.PA | PHARNEXT | Issy-les-Moulineaux | France | EUR | PAR | 2.86 | -0.65 | 40 | https://www.pharnext.com |
1177.HK | SINO BIOPHARM | Wan Chai | Hong Kong | HKD | HKG | 0.48 | 17.58 | 25579 | https://www.sinobiopharm.com |
0775.HK | CKLIFE SCIENCES | Tai Po | Hong Kong | HKD | HKG | 0.40 | 32.46 | 1855 | https://www.ck-lifesciences.com |
DNA | Ginkgo Bioworks Holdings, Inc. | Boston | United States | USD | NYQ | -1.24 | 641 | https://www.ginkgobioworks.com | |
002252.SZ | S/H RAAS BLOOD PRO | Shanghai | China | CNY | SHZ | 0.21 | 19.62 | 2966 | https://www.raas-corp.com |
002007.SZ | HUALAN BIOLOGICAL | Xinxiang | China | CNY | SHZ | 0.03 | 19.25 | 2927 | https://www.hualanbio.com |
600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | Suzhou | China | CNY | SHH | 0.56 | -710.43 | https://www.600200.com | |
600866.SS | STAR LAKE BIOSCIENCE CO INC Z | Zhaoqing | China | CNY | SHH | 0.35 | 21.35 | 2608 | https://www.starlake.com.cn |
TRX.L | TISSUE REGENIX GROUP PLC | Garforth | United Kingdom | GBp | LSE | 1.40 | -10.94 | 79 | https://www.tissueregenix.com |
2269.HK | WUXI BIO | Wuxi | China | HKD | HKG | 0.91 | 85.17 | 9864 | https://www.wuxibiologics.com |
IMU.AX | IMUGENE FPO | Sydney | Australia | AUD | ASX | 2.28 | -30.30 | https://www.imugene.com | |
600201.SS | JINYU BIO-TECHNOLOGY CO LTD | Hohhot | China | CNY | SHH | 0.31 | 18.76 | 1580 | https://www.jinyu.com.cn |
TMBR | Timber Pharmaceuticals, Inc. | Basking Ridge | United States | USD | ASE | 0.19 | 5 | https://www.timberpharma.com | |
300181.SZ | ZHEJIANG JOLLY PHA | Huzhou | China | CNY | SHZ | 0.10 | 18.50 | 2132 | https://www.zuoli.com |
CLVS | Clovis Oncology, Inc. | Boulder | United States | USD | NMS | 0.49 | -3.78 | 413 | https://www.clovisoncology.com |
ATHX | Athersys, Inc. | Cleveland | United States | USD | NCM | -1.30 | -0.60 | 104 | https://www.athersys.com |
VTGN | VistaGen Therapeutics, Inc. | South San Francisco | United States | USD | NCM | 1.06 | 0.75 | 36 | https://www.vistagen.com |
300009.SZ | ANHUI ANKE BIOTECH | Hefei | China | CNY | SHZ | 0.38 | 19.32 | https://www.ankebio.com | |
300122.SZ | CHONGQING ZHIFEI B | Chongqing | China | CNY | SHZ | 0.77 | 11.89 | 4800 | https://www.zhifeishengwu.com |
2370.T | MEDINET CO LTD | Tokyo | Japan | JPY | JPX | 1.34 | -2.69 | 92 | https://www.medinet-inc.co.jp |
2137.HK | BRII-B | Beijing | China | HKD | HKG | -5.41 | 113 | https://www.briibio.com | |
1530.HK | 3SBIO | Shenyang | China | HKD | HKG | 0.84 | 6.75 | 5292 | https://www.3sbio.com |
1801.HK | INNOVENT BIO | Suzhou | China | HKD | HKG | -0.31 | -14.04 | 5568 | https://www.innoventbio.com |
300497.SZ | JIANGXI FUSHINE PH | Jingdezhen | China | CNY | SHZ | 0.14 | 35.19 | 1849 | https://www.fushine.cn |
300147.SZ | XIANGXUE PHARMACEU | Guangzhou | China | CNY | SHZ | 0.59 | 374.63 | 3378 | https://www.xphcn.com |
BLUE | bluebird bio, Inc. | Cambridge | United States | USD | NMS | 1.38 | -0.35 | 518 | https://www.bluebirdbio.com |
300204.SZ | STAIDSON (BEIJING) | Beijing | China | CNY | SHZ | 0.16 | -27.06 | 873 | https://www.staidson.com |
AKBA | Akebia Therapeutics, Inc. | Cambridge | United States | USD | NGM | 1.47 | -0.16 | 426 | https://www.akebia.com |
1873.HK | VIVA BIOTECH | Shanghai | China | HKD | HKG | 0.95 | 15.94 | 2127 | https://www.vivabiotech.com.cn |
300363.SZ | PORTON PHARMA SOLU | Chongqing | China | CNY | SHZ | -0.36 | 30.90 | 4158 | https://www.porton.cn |
VLON | Vallon Pharmaceuticals Inc. | Philadelphia | United States | USD | NCM | -1.15 | -0.24 | 2 | https://www.vallon-pharma.com |
SRNE | Sorrento Therapeutics, Inc. | San Diego | United States | USD | NCM | 2.17 | -2.59 | 799 | https://www.sorrentotherapeutics.com |
NVAX | Novavax, Inc. | Gaithersburg | United States | USD | NMS | 1.58 | -2.58 | 1541 | https://www.novavax.com |
300759.SZ | PHARMARON BEIJING | Beijing | China | CNY | SHZ | 0.28 | 49.23 | 14923 | https://www.pharmaron.com |
300404.SZ | BOJI MEDICAL & TEC | Guangzhou | China | CNY | SHZ | -0.10 | 63.41 | 989 | https://www.bojicro.com |
RIGL | Rigel Pharmaceuticals, Inc. | South San Francisco | United States | USD | NMS | 1.66 | -2.33 | 165 | https://www.rigel.com |
688180.SS | SHANGHAI JUNSHI BIOSCIENCES CO | Shanghai | China | CNY | SHH | 0.24 | -39.92 | 2805 | https://www.junshipharma.com |
600161.SS | BEIJING TIANTAN BIOLOGICAL PROD | Beijing | China | CNY | SHH | 0.02 | 23.29 | 3933 | https://www.tiantanbio.com |
9939.HK | KINTOR PHARMA-B | Suzhou | China | HKD | HKG | -0.77 | -5.99 | 316 | https://www.kintor.com.cn |
VERU | Veru Inc. | Miami | United States | USD | NCM | -0.41 | -41.18 | 252 | https://www.verupharma.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.